Click here to receive MS news via e-mail
Data from the CARE-MS II clinical trial showed that Lemtrada(alemtuzumab) can lessen pre-existing disabilities in patients with relapsing-remitting multiple sclerosis (RRMS) who failed to respond adequately to previous disease-modifying therapies, according to a study of the trial’s data. The treatment was evaluated against Rebif(interferon beta-1a) therapy.
The study, “Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients” was published in the journal Neurology.
A major aim of multiple sclerosis (MS) treatment is limiting patients’ disability, an outcome usually measured by the delay in confirmed disability worsening (CDW). However, interest in growing in efforts to reach confirmed disability improvement (CDI), a higher standard of therapeutic efficacy than that of slowing disability accumulation.
CDI is believed to reflect durable and clinically meaningful Expanded Disability Status Scale (EDSS) score changes. EDSS is a standard method of quantifying disability in MS.
In this study, the researchers’ objective was to characterize the effects of Lemtrada treatment on measures of disability improvement in patients with RRMS whose response to other treatments was found to be inadequate (relapsing at least once). Lemtrada is a humanized monoclonal antibody capable of remodeling the immune responses of innate immune cells in patients with RRMS.
MS Views and News
Providing educational information, resources and services for those affected by MS
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews